Could a lower dose of enzalutamide work better for elderly prostate cancer patients?

NCT ID NCT07512076

Not yet recruiting Knowledge-focused Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing four different doses of enzalutamide (40, 80, 120, and 160 mg) in men aged 75 and older with advanced prostate cancer. The goal is to see how drug levels in the blood differ between older and younger patients, and to find the safest and most effective dose. The study will enroll 26 participants and may adjust doses after 8 weeks based on how well the treatment is working.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enzalutamide
What this could lead to: If successful, this study could help doctors choose the right enzalutamide dose for older patients, potentially improving treatment outcomes and reducing side effects.
What could go wrong: This is a small, early-phase study with only 26 participants, so results may not apply to all patients. It focuses on drug levels in the blood, not direct proof of better cancer control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ELDERLY PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ELDERLY PATIENTS PHARMACOKINETIC STUDY PROSTATE CANCER PATIENTS

Contacts and locations

Locations

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.